|
|
Article: Intrexon Follows RheoGene Merger With $25M Series C1.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Preclinical gene therapy company Intrexon Corp. pulled down $25 million in a Series C1 round backed entirely by venture capital firm Third Security LLC.
The financing brings the total private equity investment in Blacksburg, Va.-based Intrexon to $32.3 million, most of it provided through funds managed by Radford, Va.-based Third Security.
Intrexon CEO Robert Beech said the funds will support the company's efforts to advance its lead gene therapy program for melanoma into clinical trials by the end of the year, pending regulatory approvals. A program in glioma is "not far behind," he said, adding that Intrexon is interesting in ...